Immune escape mechanisms as a guide for cancer immunotherapy
about
Uveal melanoma as a target for immune-therapyIntrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and FunctionThe potential of tumor-derived exosomes for noninvasive cancer monitoringGenetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery.The multifaceted role of autophagy in tumor evasion from immune surveillanceHigh-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cellsA new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Escape from IFN-γ-dependent immunosurveillance in tumorigenesis.Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognosticCTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer.Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps.Advances and challenges: dendritic cell vaccination strategies for glioblastoma.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.Functio Laesa: Cancer Inflammation and Therapeutic Resistance.Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.Cytokines in immunogenic cell death: Applications for cancer immunotherapy.A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer.Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.Leveraging natural killer cells for cancer immunotherapy.miRNAs, Melanoma and Microenvironment: An Intricate Network.Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.CAR-T cells and combination therapies: What's next in the immunotherapy revolution?The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy.Tumor-associated CD204+ M2 macrophages is an unfavorable prognosticator in uterine cervical adenocarcinoma.Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides.Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression.Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells.Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts.MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer.Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.
P2860
Q26747519-F68B904E-358E-45D2-8C68-77DAD82DA006Q26749556-54E58854-9F7C-4C1E-BC4C-0AAAB6FDF055Q26796396-BB00EF28-5BA9-4758-9559-52AA7A8B0DF2Q37024754-8F8A08A8-82F4-478E-AFC7-683C92E22773Q37109549-F52B6A43-E505-4843-B6ED-C1FF595119C5Q37376726-24FCCA68-D238-4D7E-8375-DEB62CB89260Q37555940-AF797B9C-8B85-42A4-833E-B5BE824CDE47Q37566921-95FAF293-B92F-404B-9B58-DB08430E09C2Q37618482-0CF1170E-A40F-49C0-9C3A-AE0E15BE8427Q37716378-6379ECC1-91DA-485B-8074-A01A3A0CE867Q38601221-F2CA3FDB-B14D-4464-843A-7FCCBDF6F683Q38753955-2103AC6A-464D-4F8B-932D-54B3F5668200Q38786054-0D190CFA-8D01-48E9-9AB7-316CD638B4EAQ38823649-68181454-9F29-495F-AEF0-DBE0B6664814Q38845812-BC2532EC-7857-4D68-8562-6502EB315714Q38921652-E1447BBE-6204-4AC9-94A3-B17951CCE6DEQ38984929-17ED8389-FF72-4911-8248-22A2BF12C26AQ38988078-91C51464-BE14-4AB8-BA32-B6353C616C34Q39172861-75D71BAB-B340-4E40-B250-4960CBAB2CC1Q39308337-4C474357-91D5-4BC1-B91C-B995C7C66CE6Q39397491-83FF48B8-0FAF-4A29-BC5D-543CEDCE7956Q41348794-7C09A1B7-B317-481D-84D1-F237C60F8BCCQ41463557-930AB3E7-DF43-4D7C-9A9F-F783219E8389Q41718196-EAC2BAF8-F4A2-40AE-88C3-8703CD1A90FDQ43865719-81CE5071-D80A-4F40-AB2A-9AEA2EF31388Q47152593-DED70895-6446-40AA-BE3A-7E609E4373F0Q47209071-57D3C7CD-0B9B-4ABC-B326-6F6AFDBE6D4EQ47285613-8F28ADB8-2541-4919-AD57-C49824184E7FQ47337961-B9E5480C-0692-4A2E-BB98-0E123A56B6D4Q47560973-98624CD0-C9DD-497B-994C-C7E36841AF9AQ47571555-09328F58-A360-4094-B19A-DCADDBF2B04EQ47902181-819B523F-B74E-464D-AFDE-F40052A48F0DQ48097366-1BB89694-E8B9-437A-8B06-845E6E8CA0B7Q49592892-6271C121-D66D-4D2F-B05D-F61875A22755Q49609112-EE6DA27F-1AE4-4774-8022-5C5308698306Q50027827-EFA2BF94-DA99-4E27-BA6C-07BAB1CB785EQ50128059-A3969514-6BA0-499E-87A2-16DCE5810A00Q52353619-89CDD371-A24B-4C44-8F98-776D0BDD6065Q52595263-B08C1AAC-1953-44E0-AC8E-48964A923F39Q52649833-294AD947-BA00-4A0C-A2D7-AD4DE80E0C17
P2860
Immune escape mechanisms as a guide for cancer immunotherapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Immune escape mechanisms as a guide for cancer immunotherapy
@ast
Immune escape mechanisms as a guide for cancer immunotherapy
@en
Immune escape mechanisms as a guide for cancer immunotherapy
@nl
type
label
Immune escape mechanisms as a guide for cancer immunotherapy
@ast
Immune escape mechanisms as a guide for cancer immunotherapy
@en
Immune escape mechanisms as a guide for cancer immunotherapy
@nl
prefLabel
Immune escape mechanisms as a guide for cancer immunotherapy
@ast
Immune escape mechanisms as a guide for cancer immunotherapy
@en
Immune escape mechanisms as a guide for cancer immunotherapy
@nl
P2860
P3181
P1476
Immune escape mechanisms as a guide for cancer immunotherapy
@en
P2093
Whitney L Gladney
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-14-1860
P407
P577
2014-12-12T00:00:00Z